Showing 41-50 of 2442 results for "".
MS Masters Toolbox: Fatigue
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-masters-toolbox-fatigue/31167/In this series, Vito Arena, MD and Ilya Kister, MD from the New York University School of Medicine Comprehensive MS Care Center discuss tools for managing multiple sclerosis symptoms. These gems are guided by research and intended to improve quality of life for people with MS. Episode 2 provides tooDiscussing Disparities in MS Care for Underrepresented Populations
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/discussing-disparities-in-ms-care-for-underrepresented-populations/30085/In this episode, Trisham Gyang, MD, Clinical Assistant Professor of Neurology, The Ohio State University Wexner Medical Center, and Gopika Govindan Kutty, MD, Fellow, Department of Neurology, The Ohio State University Wexner Medical Center, provide strategies to assess biologic, genetic, and socialMS Masters Toolbox: Cramps, Spasms, and Spasticity
https://practicalneurology.com/programs/practical-neurology/cramps-spasms-and-spasticity/31200/In this series, Vito Arena, MD and Ilya Kister, MD from the New York University School of Medicine Comprehensive MS Care Center discuss tools for managing multiple sclerosis symptoms. These gems are guided by research and intended to improve quality of life for people with MS. Episode 4 provides tooAdult-Onset Cerebellar Ataxias
https://practicalneurology.com/diseases-diagnoses/movement-disorders/adult-onset-cerebellar-ataxias/31221/Pravin Khemani, MD, Medical Director, Movement Disorders Program, Swedish Neuroscience Institute, provides a framework for evaluation of adult-onset cerebellar ataxias.A Mark of Success?
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/a-mark-of-success/31075/Achim Schneeberger, MD, talks about the Phase II study that demonstrated clinical and biomarker effects consistent with disease modification in Alzheimer's. (headphones recommended)- How to Handle “High-Maintenance” Patientshttps://practicalneurology.com/columns/practice-management/how-to-handle-high-maintenance-patients/31354/Managing patients with chronic headaches and other pain conditions presents significant challenges, particularly when psychiatric comorbidities or substance abuse are involved. In her article for Practical Neurology, Dawn C. Buse, PhD, outlines strategies for healthcare professionals to effectively
- Taking a Closer Look at AED Drug Interactionshttps://practicalneurology.com/columns/practice-management/taking-a-closer-look-at-aed-drug-interactions/31394/Understanding Drug Interactions in Antiepileptic TherapyManaging epilepsy effectively requires a comprehensive understanding of antiepileptic drug (AED) interactions, which can significantly impact patient outcomes. In their September 2005 article in *Practical Neurology*, Angela K. Birnbaum, PhD, a
November/December 2015 Case Challenge: A 70-Year-Old Man with a Sudden Lisp
https://practicalneurology.com/diseases-diagnoses/neuromuscular/novemberdecember-2015-case-challenge-a-70-year-o/31086/By Mohanad Alzubaidi, MD and Aziz Shaibani, MD, FACP, FAAN, FANA A 70-year-old man presented with a six-month history of a "lisp," noted by his friends, that got worse the more he spoke. There was no diplopia, ptosis, dysphagia, muscle wasting, or extremities weakness. Since he was stresse- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31295/Management of Acute Seizures and Long-Term Antiepileptic Therapy: A Case StudyIn a recent article by Niranjan Siva, MD, and Amit Verma, MD, published in *Practical Neurology*, a 24-year-old male experienced two first-time generalized tonic-clonic seizures without aura within a two-hour period. Initi
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
https://practicalneurology.com/programs/practical-neurology/trials-in-2/35433/Christopher Moertel, MD, Medical Director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota provides an overview of the ReNeu clinical trial which evaluated the safety, effectiveness, and tolerability of Gomekli in children aged ≥2 years and adults.